临床肝胆病杂志

参考文献

[1]OTT JJ,STEVENS GA,GROEGER J,et al.Global epidemiology of hepatitis B virus infection:new estimates of age-specific HBsA g seroprevalence and endemicity[J].Vaccine,2012,30(12):2212-2219.

[2]LOZANO R,NAGHAVI M,FOREMAN K,et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010[J].Lancet,2012,380(9859):2095-2128.

[3]GOLDSTEIN ST,ZHOU F,HADLER SC,et al.A mathematical model to estimate global hepatitis B disease burden and vaccination impact[J].Int J Epidemiol,2005,34(6):1329-1339.

[4]WANG FS,FAN JG,ZHANG Z,et al.The global burden of liver disease:the major impact of China[J].Hepatology,2014,60(6):2099-2108.

[5]FUNG J,SETO WK,LAI CL,et al.Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B:implications for antiviral therapy[J].J Hepatol,2011,54(2):195-200.

[6]LIANG X,BI S,YANG W,et al.Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination[J].Vaccine,2009,27(47):6550-6557.

[7]LIANG X,BI S,YANG W,et al.Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China[J].J Infect Dis,2009,200(1):39-47.

[8]LU FM,ZHUANG H.Management of hepatitis B in China[J].Chin Med J(Engl),2009,122(1):3-4.

[9]World Health Organization.Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection[R].Geneva:WHO,2015.

[10]MAST EE,MARGOLIS HS,FIORE AE,et al.A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States:recommendations of the Advisory Committee on Immunization Practices(ACIP)part 1:immunization of infants,children,and adolescents[J].MMWR Recomm Rep,2005,54(rr-16):1-31.

[11]Chinese Center for Disease Control and Prevention.Management regulations for hepatitis B vaccination as the planned immunization for children(trial implementation)[S].Beijing:2002.(in Chinese)中国疾病预防控制中心.乙型肝炎疫苗儿童计划免疫技术管理规程(试行).2002.

[12]XIA GL,GONG J,WANG JJ,et al.Efficacy of recombinant hepatitis B and low-dose hepatitis B immune globulin in preventing mother-infant transmission of hepatitis B virus infection[J].Chin J Epidemiol,2003,24(5):362-365.(in Chinese)夏国良,龚健,王继杰,等.重组乙型肝炎疫苗阻断乙型肝炎病毒母婴传播方案的保护效果评价[J].中华流行病学杂志,2003,24(5):362-365.

[13]SINGH AE,PLITT SS,OSIOWY C,et al.Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants[J].J Viral Hepat,2011,18(7):468-473.

[14]TRAN TT.Management of hepatitis B in pregnancy:weighing the options[J].Cleve Clin J Med,2009,76(Suppl 3):s25-s29.

[15]HAN L,ZHANG HW,XIE JX,et al.A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus[J].World J Gastroenterol,2011,17(38):4321-4333.

[16]HAN GR,CAO MK,ZHAO W,et al.A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J].J Hepatol,2011,55(6):1215-1221.

[17]PAN CQ,MI LJ,BUNCHORNTAVAKUL C,et al.Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women:a case series[J].Dig Dis Sci,2012,57(9):2423-2429.

[18]ZANETTI AR,MARIANO A,ROMANO L,et al.Long-term immunogenicity of hepatitis B vaccination and policy for booster:an Italian multicentre study[J].Lancet,2005,366(9494):1379-1384.

[19]U.S.Public Health Service.Updated U.S.public health service guidelines for the management of occupational exposures to HBV,HCV,and HIV and recommendations for postexposure prophylaxis[J].MMWR Recomm Rep,2001,50(rr-11):1-52.

[20]YAN H,ZHONG G,XU G,et al.Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J].Elife,2012,1:e00049.

[21]LIU CJ,KAO JH.Global perspective on the natural history of chronic hepatitis B:role of hepatitis B virus genotypes A to J[J].Semin Liver Dis,2013,33(2):97-102.

[22]LIN CL,KAO JH.The clinical implications of hepatitis B virus genotype:recent advances[J].J Gastroenterol Hepatol,2011,26(Suppl 1):123-130.

[23]LIVINGSTON SE,SIMONETTI JP,BULKOW LR,et al.Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A,B,C,D,and F[J].Gastroenterology,2007,133(5):1452-1457.

[24]YU MW,YEH SH,CHEN PJ,et al.Hepatitis B virus genotype and DNA level and hepatocellular carcinoma:a prospective study in men[J].J Natl Cancer Inst,2005,97(4):265-272.

[25]LIM SG,CHENG Y,GUINDON S,et al.Viral quasi-species evolution during hepatitis Be antigen seroconversion[J].Gastroenterology,2007,133(3):951-958.

[26]WANG HY,CHIEN MH,HUANG HP,et al.Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases[J].J Virol,2010,84(7):3454-3463.

[27]LIU F,CHEN L,YU DM,et al.Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures:correlation with antiviral efficacy[J].Gut,2011,60(9):1269-1277.

[28]LAI CL,RATZIU V,YUEN MF,et al.Viral hepatitis B[J].Lancet,2003,362(9401):2089-2094.

[29]LIAW YF.Natural history of chronic hepatitis B virus infection and long-term outcome under treatment[J].Liver Int,2009,29(Suppl 1):100-107.

[30]HUI CK,LEUNG N,YUEN ST,et al.Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase[J].Hepatology,2007,46(2):395-401.

[31]McM AHON BJ.The natural history of chronic hepatitis B virus infection[J].Hepatology,2009,49(5 Suppl):s45-s55.

[32]LIAW YF.Hepatitis flares and hepatitis B e antigen seroconversion:implication in anti-hepatitis B virus therapy[J].J Gastroenterol Hepatol,2003,18(3):246-252.

[33]CHU CM,HUNG SJ,LIN J,et al.Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels[J].Am J Med,2004,116(12):829-834.

[34]CHU CM,LIAW YF.Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers[J].Clin Infect Dis,2012,54(1):88-90.

[35]CHU CM,LIAW YF.Hepatitis B surface antigen seroclearance during chronic HBV infection[J].Antivir Ther,2010,15(2):133-143.

[36]FATTOVICH G,BORTOLOTTI F,DONATO F.Natural history of chronic hepatitis B:special emphasis on disease progression and prognostic factors[J].J Hepatol,2008,48(2):335-352.

[37]CHEN YC,CHU CM,LIAW YF.Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B[J].Hepatology,2010,51(2):435-444.

[38]PARK BK,PARK YN,AHN SH,et al.Long-term outcome of chronic hepatitis B based on histological grade and stage[J].J Gastroenterol Hepatol,2007,22(3):383-388.

[39]LIN SM,YU ML,LEE CM,et al.Interferon therapy in HBeA g positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma[J].J Hepatol,2007,46(1):45-52.

[40]YIM HJ,LOK AS.Natural history of chronic hepatitis B virus infection:what we knew in 1981 and what we know in 2005[J].Hepatology,2006,43(2 Suppl 1):s173-s181.

[41]CHU CM,LIAW YF.Hepatitis B virus-related cirrhosis:natural history and treatment[J].Semin Liver Dis,2006,26(2):142-152.

[42]CHEN YC,CHU CM,YEH CT,et al.Natural course following the onset of cirrhosis in patients with chronic hepatitis B:a long-term follow-up study[J].Hepatol Int,2007,1(1):267-273.

[43]HSU YS,CHIEN RN,YEH CT,et al.Long-term outcome after spontaneous HBeA g seroconversion in patients with chronic hepatitis B[J].Hepatology,2002,35(6):1522-1527.

[44]McM AHON BJ,HOLCK P,BULKOW L,et al.Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus[J].Ann Intern Med,2001,135(9):759-768.

[45]FATTOVICH G,GIUSTINA G,SCHALM SW,et al.Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B.The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis[J].Hepatology,1995,21(1):77-82.

[46]FATTOVICH G.Natural history and prognosis of hepatitis B[J].Semin Liver Dis,2003,23(1):47-58.

[47]TSENG TC,LIU CJ,YANG HC,et al.Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads[J].Hepatology,2013,57(2):441-450.

[48]TSENG TC,LIU CJ,YANG HC,et al.High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load[J].Gastroenterology,2012,142(5):1140-1149.

[49]DANDRI M,LOCARNINI S.New insight in the pathobiology of hepatitis B virus infection[J].Gut,2012,61(Suppl 1):i6-i17.

[50]ZHANG Z,ZHANG JY,WANG LF,et al.Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection[J].J Gastroenterol Hepatol,2012,27(2):223-230.

[51]ISOGAWA M,TANAKA Y.Immunobiology of hepatitis B virus infection[J].Hepatol Res,2015,45(2):179-189.

[52]GUIDOTTI LG,CHISARI FV.Noncytolytic control of viral infections by the innate and adaptive immune response[J].Annu Rev Immunol,2001,19:65-91.

[53]BERTOLETTI A,FERRARI C.Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection[J].Gut,2012,61(12):1754-1764.

[54]FAN R,SUN J,YUAN Q,et al.Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeA g seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues[J].Gut,2015.[Epub ahead of print]

[55]HOU FQ,SONG LW,YUAN Q,et al.Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeA g-positive chronic hepatitis B patients receiving peginterferon[J].Theranostics,2015,5(3):218-226.

[56]LAMPERTICO P,MAINI M,PAPATHEODORIDIS G.Optimal management of hepatitis B virus infection-EASL Special Conference[J].J Hepatol,2015,63(5):1238-1253.

[57]LIAW YF,KAO JH,PIRATVISUTH T,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012update[J].Hepatol Int,2012,6(3):531-561.

[58]Ministry of Health of the People's Republic of China.Updated standards for the diagnosis and treatment of primary liver cancer[J].Chin J Hepatol,2012,20(6):419-426.(in Chinese)中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)摘要[J].中华肝脏病杂志,2012,20(6):419-426.

[59]WONG GL,CHAN HL,TSE YK,et al.On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir[J].Hepatology,2014,59(3):986-995.

[60]HANN HW,FU X,MYERS RE,et al.Predictive value of alphafetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection-results from a clinic-based longitudinal cohort[J].Eur J Cancer,2012,48(15):2319-2327.

[61]AMADDEO G,CAO Q,LADEIRO Y,et al.Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas[J].Gut,2015,64(5):820-829.

[62]MARRERO JA,SU GL,WEI W,et al.Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients[J].Hepatology,2003,37(5):1114-1121.

[63]INAGAKI Y,TANG W,MAKUUCHI M,et al.Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-gamma-carboxyprothrombin[J].Liver Int,2011,31(1):22-35.

[64]SEO SI,KIM HS,KIM WJ,et al.Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma[J].World J Gastroenterol,2015,21(13):3928-3935.

[65]WAI CT,GREENSON JK,FONTANA RJ,et al.A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J].Hepatology,2003,38(2):518-526.

[66]SCOTT DR,LEVY MT.Liver transient elastography(Fibroscan):a place in the management algorithms of chronic viral hepatitis[J].Antivir Ther,2010,15(1):1-11.

[67]SHAHEEN AA,WAN AF,MYERS RP.FibroT est and FibroS can for the prediction of hepatitis C-related fibrosis:a systematic review of diagnostic test accuracy[J].Am J Gastroenterol,2007,102(11):2589-600.

[68]European Association for Study of Liver,Asociacion Latinoamericana para el Estudio del Higado.EASL-ALEH Clinical Practice Guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis[J].J Hepatol,2015,63(1):237-264.

[69]Review Panel for Liver Stiffness Measurement.Recommendations for the clinical application of transient elastography in liver fibrosis assessment[J].Chin J Hepatol,2013,21(6):420-424.(in Chinese)肝脏硬度评估小组.瞬时弹性成像技术诊断肝纤维化专家意见[J].中华肝脏病杂志,2013,21(6):420-424.

[70]JIA J,HOU J,DING H,et al.Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B[J].J Gastroenterol Hepatol,2015,30(4):756-762.

[71]CHANG TT,LIAW YF,WU SS,et al.Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J].Hepatology,2010,52(3):886-893.

[72]MARCELLIN P,GANE E,BUTI M,et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study[J].Lancet,2013,381(9865):468-475.

[73]LI W,ZHAO J,ZOU Z,et al.Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naive patients with acute and chronic HBV infection[J].PLoS One,2014,9(2):e89046.

[74]BEDOSSA P,POYNARD T.An algorithm for the grading of activity in chronic hepatitis C.The METAVIR Cooperative Study Group[J].Hepatology,1996,24(2):289-293.

[75]XU S,WANG Y,TAI DC,et al.q Fibrosis:a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients[J].J Hepatol,2014,61(2):260-269.

[76]DING H,MA JJ,WANG WP,et al.Assessment of liver fibrosis:the relationship between point shear wave elastography and quantitative histological analysis[J].J Gastroenterol Hepatol,2015,30(3):553-558.

[77]GANEM D,PRINCE AM.Hepatitis B virus infection-natural history and clinical consequences[J].N Engl J Med,2004,350(11):1118-1129.

[78]European Association For The Study of The Liver.EASL clinical practice guidelines:Management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.

[79]Experts in combined team of the major special project of Ministry of Science and Technology supported by China’s“Twelfth five-Year plan”.Management of clinical diagnosis,evaluation,and antiviral therapy for HBV-related cirrhosis[J].J Chin Hepatol,2014,30(2):99-108.(in Chinese)科技部十二五重大专项联合课题组.乙型肝炎病毒相关肝硬化的临床诊断、评估和抗病毒治疗的综合管理[J].临床肝胆病杂志,2014,30(2):99-108.

[80]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention andtreatment for chronic hepatitis B(2010 version)[J].Chin J Hepatol,2011,19(1):13-24.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].中华肝脏病杂志,2011,19(1):13-24.

[81]ARVANITI V,D'AMICO G,FEDE G,et al.Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J].Gastroenterology,2010,139(4):1246-1256,1256.e1-e5.

[82]TSOCHATZIS EA,BOSCH J,BURROUGHS AK.Liver cirrhosis[J].Lancet,383(9930):1749-1761.

[83]CAVIGLIA GP,ABATE ML,PELLICANO R,et al.Chronic hepatitis B therapy:available drugs and treatment guidelines[J].Minerva Gastroenterol Dietol,2015,61(2):61-70.

[84]VALLET-PICHARD A,POL S.Hepatitis B virus treatment beyond the guidelines:special populations and consideration of treatment withdrawal[J].Therap Adv Gastroenterol,2014,7(4):148-155.

[85]TANG CM,YAU TO,YU J.Management of chronic hepatitis B infection:current treatment guidelines,challenges,and new developments[J].World J Gastroenterol,2014,20(20):6262-6278.

[86]ZHAO H,KURBANOV F,WAN MB,et al.Genotype B and younger patient age associated with better response to low-dose therapy:a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China[J].Clin Infect Dis,2007,44(4):541-548.

[87]LIAW YF,JIA JD,CHAN HL,et al.Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C[J].Hepatology,2011,54(5):1591-1599.

[88]BUSTER EH,FLINK HJ,CAKALOGLU Y,et al.Sustained HBeA g and HBsA g loss after long-term follow-up of HBeA g-positive patients treated with peginterferon alpha-2b[J].Gastroenterology,2008,135(2):459-467.

[89]MARCELLIN P,BONINO F,YURDAYDIN C,et al.Hepatitis B surface antigen levels:association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients[J].Hepatol Int,2013,7(1):88-97.

[90]LAMPERTICO P,VIGANòM,COLOMBO M.Treatment of HBeA g-negative chronic hepatitis B with pegylated interferon[J].Liver Int,2011,31(Suppl 1):90-94.

[91]LAMPERTICO P,VIGANO M,DI COSTANZO GG,et al.Randomised study comparing 48 and 96 weeks peginterferonα-2a therapy in genotype D HBeA g-negative chronic hepatitis B[J].Gut,2013,62(2):290-298.

[92]KIM V,ABREU RM,NAKAGAWA DM,et al.Pegylated interferon alfa for chronic hepatitis B:systematic review and meta-analysis[J].J Viral Hepat,2015.[Epub ahead of print]

[93]WONG GL,WONG VW,CHAN HL.Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B[J].J Viral Hepat,2014,21(12):825-834.

[94]MARCELLIN P,AHN S,MA X,et al.HBsA g loss with tenofovir disoproxil fumarate(TDF)plus peginterferon alfa-2a(PEG)in chronic hepatitis B(CHB):results of a global randomized controlled trial[J].Hepatology,2014,60:294a-295a.

[95]XIE Q,ZHOU H,BAI X,et al.A randomized,open-label clinical study of combined pegylated interferon Alfa-2a(40KD)and entecavir treatment for hepatitis B"e"antigen-positive chronic hepatitis B[J].Clin Infect Dis,2014,59(12):1714-1723.

[96]CHI H,XIE Q,ZHANG N,et al.Addition of peginterferon alfa-2b during long-term nucleos(t)ide analogue therapy increases HBeA g seroconversion and HBsA g decline-week 48 results from a multicenter randomized controlled trial(PEGON study)[J].Hepatology,2014,60:1106a.

[97]NING Q,HAN M,SUN Y,et al.Switching from entecavir to PegI FN alfa-2a in patients with HBeA g-positive chronic hepatitis B:a randomised open-label trial(OSST trial)[J].J Hepatol,2014,61(4):777-784.

[98]HU P,JIA S,ZHANG W,et al.A multi-center randomized study on the efficacy and safety of switching to peginterferon alpha-2a(40KD)for 48 or 96 weeks in HBeA g positive CHB patients with a prior NUC history for 1 to 3 years:an interim analysis of NEW SWITCH study[J].Hepatology,2014,60(6):1273a-1274a.

[99]BROUWER WP,XIE Q,SONNEVELD MJ,et al.Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B:A multicenter randomized trial(ARES study)[J].Hepatology,2015,61(5):1512-1522.

[100]LI G,YU Y,CHEN S,et al.Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen(HBeA g)seroconversion in HBeA g-positive chronic hepatitis B patients receiving long-term entecavir treatment[J].Antimicrob Agents Chemother,2015,59(7):4121-4128.

[101]SONNEVELD MJ,HANSEN BE,PIRATVISUTH T,et al.Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels[J].Hepatology,2013,58(3):872-880.

[102]SARRI G,WESTBY M,BERMINGHAM S,et al.Diagnosis and management of chronic hepatitis B in children,young people,and adults:summary of NICE guidance[J].BMJ,2013,346:f3893.

[103]RIJCKBORST V,HANSEN BE,FERENCI P,et al.Validation of a stopping rule at week 12 using HBsA g and HBV DNA for HBeA g-negative patients treated with peginterferon alfa-2a[J].J Hepatol,2012,56(5):1006-1011.

[104]CHANG TT,GISH RG,de MAN R,et al.A comparison of entecavir and lamivudine for HBeA g-positive chronic hepatitis B[J].N Engl J Med,2006,354(10):1001-1010.

[105]LAI CL,SHOUVAL D,LOK AS,et al.Entecavir versus lamivudine for patients with HBeA g-negative chronic hepatitis B[J].N Engl J Med,2006,354(10):1011-1020.

[106]CHANG TT,LAI CL,KEW YOON S,et al.Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B[J].Hepatology,2010,51(2):422-430.

[107]TENNEY DJ,ROSE RE,BALDICK CJ,et al.Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy[J].Hepatology,2009,49:1503-1514.

[108]LOK AS.Hepatitis:Long-term therapy of chronic hepatitis B reverses cirrhosis[J].Nat Rev Gastroenterol Hepatol,2013,10(4):199-200.

[109]MARCELLIN P,HEATHCOTE EJ,BUTI M,et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J].N Engl J Med,2008,359(23):2442-2455.

[110]Marcellin P,Flisiak R,Trinh H,et al.Long term treatment with tenofovir disoproxil fumarate for chronic hepatitis B infection is safe and well tolerated and associated with durable virologic response with no detectable resistance:8 year results from two phase 3 trials[J].Hepatology,2014,60:313a-314a.

[111]FUNG S,KWAN P,FABRI M,et al.Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B[J].Gastroenterology,2014,146(4):980-988.

[112]LIM YS,YOO BC,BYUN KS,et al.Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure:results of a randomised trial[J].Gut,2015.[Epub ahead of print]

[113]PATTERSON SJ,GEORGE J,STRASSER SI,et al.Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B[J].Gut,2011,60(2):247-254.

[114]BERG T,ZOULIM F,MOELLER B,et al.Long-term efficacy and safety of emtricitabine plus tenofovir DF vs.tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients[J].J Hepatol,2014,60(4):715-722.

[115]HOU J,YIN YK,XU D,et al.Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B:results at 1 year of a randomized,double-blind trial[J].Hepatology,2008,47(2):447-454.

[116]LIAW YF,GANE E,LEUNG N,et al.2-Year GLOBE trial results:telbivudine is superior to lamivudine in patients with chronic hepatitis B[J].Gastroenterology,2009,136(2):486-495.

[117]SUN J,XIE Q,TAN D,et al.The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients:a randomized,controlled study[J].Hepatology,2014,59(4):1283-1292.

[118]MARCELLIN P,CHANG TT,LIM SG,et al.Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J].Hepatology,2008,48(3):750-758.

[119]ZENG M,MAO Y,YAO G,et al.A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeA g-positive chronic hepatitis B[J].Hepatology,2006,44(1):108-116.

[120]HADZIYANNIS SJ,TASSOPOULOS NC,HEATHCOTE EJ,et al.Long-term therapy with adefovir dipivoxil for HBeA g-negative chronic hepatitis B for up to 5 years[J].Gastroenterology,2006,131(6):1743-1751.

[121]LAMPERTICO P,VIGANO M,MANENTI E,et al.Low resistance to adefovir combined with lamivudine:a 3-year study of 145lamivudine-resistant hepatitis B patients[J].Gastroenterology,2007,133(5):1445-1451.

[122]YAO GB,ZHU M,CUI ZY,et al.A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China[J].J Dig Dis,2009,10(2):131-137.

[123]LIAW YF,SUNG JJ,CHOW WC,et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease[J].N Engl J Med,2004,351(15):1521-1531.

[124]CHEN CH,LIN CL,HU TH,et al.Entecavir vs.lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation[J].J Hepatol,2014,60(6):1127-1134.

[125]LAU GK,PIRATVISUTH T,LUO KX,et al.Peginterferon Alfa-2a,lamivudine,and the combination for HBeA g-positive chronic hepatitis B[J].N Engl J Med,2005,352(26):2682-2695.

[126]JANSSEN HL,van ZONNEVELD M,SENTURK H,et al.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeA g-positive chronic hepatitis B:a randomised trial[J].Lancet,2005,365(9454):123-129.

[127]LAI CL,CHIEN RN,LEUNG NW,et al.A one-year trial of lamivudine for chronic hepatitis B.Asia Hepatitis Lamivudine Study Group[J].N Engl J Med,1998,339(2):61-68.

[128]DIENSTAG JL,SCHIFF ER,WRIGHT TL,et al.Lamivudine as initial treatment for chronic hepatitis B in the United States[J].N Engl J Med,1999,341(17):1256-1263.

[129]LAI CL,GANE E,LIAW YF,et al.Telbivudine versus lamivudine in patients with chronic hepatitis B[J].N Engl J Med,2007,357(25):2576-2588.

[130]MARCELLIN P,CHANG TT,LIM SG,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B[J].N Engl J Med,2003,348(9):808-816.

[131]GISH RG,LOK AS,CHANG TT,et al.Entecavir therapy for up to 96 weeks in patients with HBeA g-positive chronic hepatitis B[J].Gastroenterology,2007,133(5):1437-1444.

[132]MINDE Z,YIMIN M,GUANGBI Y,et al.Five years of treatment with adefovir dipivoxil in Chinese patients with HBeA g-positive chronic hepatitis B[J].Liver Int,2012,32(1):137-146.

[133]MARCELLIN P,LAU GK,BONINO F,et al.Peginterferon alfa-2a alone,lamivudine alone,and the two in combination in patients with HBeA g-negative chronic hepatitis B[J].N Engl J Med,2004,351(12):1206-1217.

[134]TASSOPOULOS NC,VOLPES R,PASTORE G,et al.Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive(precore mutant)chronic hepatitis B.Lamivudine Precore Mutant Study Group[J].Hepatology,1999,29(3):889-896.

[135]HADZIYANNIS SJ,TASSOPOULOS NC,HEATHCOTE EJ,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigennegative chronic hepatitis B[J].N Engl J Med,2003,348(9):800-807.

[136]MARCELLIN P,BONINO F,LAU GK,et al.Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a[J].Gastroenterology,2009,136(7):2169-2179.e1-4.

[137]Experts Attending the Discussion on Hepatitis B Virus Drug Resistance.Drug resistance to nucleoside and nucleotide analogs in chronic hepatitis B and its management[J].J Chin Hepatol,2013,29(1):10-17.(in Chinese)参加乙型肝炎耐药讨论会专家.核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理[J].临床肝胆病杂志,2013,29(1):10-17.

[138]SUN J,HOU JL,XIE Q,et al.Randomised clinical trial:efficacy of peginterferon alfa-2a in HBeA g positive chronic hepatitis B patients with lamivudine resistance[J].Aliment Pharmacol Ther,2011,34(4):424-431.

[139]YAPALI S,TALAAT N,FONTANA RJ,et al.Outcomes of patients with chronic hepatitis B who do not meet criteria for antiviral treatment at presentation[J].Clin Gastroenterol Hepatol,2015,13(1):193-201.e1.

[140]LOK AS,McM AHON BJ.Chronic hepatitis B:update 2009[J].Hepatology,2009,50(3):661-662.

[141]LIANG X,CHENG J,SUN Y,et al.Randomized,three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients[J].J Gastroenterol Hepatol,2015,30(4):748-755.

[142]REIJNDERS JG,PERQUIN MJ,ZHANG N,et al.Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B[J].Gastroenterology,2010,139(2):491-498.

[143]CHI H,HANSEN BE,YIM C,et al.Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B[J].Aliment Pharmacol Ther,2015,41(9):867-876.

[144]RYU SH,CHUNG YH,CHOI MH,et al.Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeA g loss:a prospective study[J].J Hepatol,2003,39(4):614-619.

[145]WANG Y,THONGSAWAT S,GANE EJ,et al.Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B[J].J Viral Hepat,2013,20(4):e37-e46.

[146]SONNEVELD MJ,HANSEN BE,PIRATVISUTH T,et al.Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels[J].Hepatology,2013,58(3):872-880.

[147]SETO WK,HUI AJ,WONG VW,et al.Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B:a multicentre prospective study[J].Gut,2015,64(4):667-672.

[148]JENG WJ,SHEEN IS,CHEN YC,et al.Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients[J].Hepatology,2013,58(6):1888-1896.

[149]BUSTER EH,HANSEN BE,BUTI M,et al.Peginterferon alpha-2b is safe and effective in HBeA g-positive chronic hepatitis B patients with advanced fibrosis[J].Hepatology,2007,46(2):388-394.

[150]CHO JY,PAIK YH,SOHN W,et al.Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease[J].Gut,2014,63(12):1943-1950.

[151]YANG YJ,SHIM JH,KIM KM,et al.Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy[J].Hepatology,2014,59(4):1303-1310.

[152]LIU CJ,CHEN PJ,CHEN DS,et al.Hepatitis B virus reactivation in patients receiving cancer chemotherapy:naturalhistory,pathogenesis,and management[J].Hepatol Int,2013,7(2):316-326.

[153]LOOMBA R,ROWLEY A,WESLEY R,et al.Systematic review:the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy[J].Ann Intern Med,2008,148:519-528.

[154]LI HR,HUANG JJ,GUO HQ,et al.Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy[J].J Viral Hepat,2011,18(12):877-883.

[155]PERRILLO RP,GISH R,FALCK-YTTER YT,et al.American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy[J].Gastroenterology,2015,148(1):221-244.

[156]HWANG JP,LOK AS.Management of patientswith hepatitis B who require immunosuppressive therapy[J].Nat Rev Gastroenterol Hepatol,2014,11(4):209-219.

[157]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2015[J].J Hepatol,2015,63(1):199-236.

[158]KONSTANTINOU D,DEUTSCH M.The spectrum of HBV/HCV coinfection:epidemiology,clinical characteristics,viralinteractions and management[J].Ann Gastroenterol,2015,28(2):221-228.

[159]LIU JY,SHENG YJ,HU HD,et al.The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection:a meta-analysis[J].Virol J,2012,9:186.

[160]KOSI L,REIBERGER T,PAYER BA,et al.Five-year ontreatment efficacy of lamivudine-,tenofovir-and tenofovir+emtricitabine-based HAART in HBV-HIV-coinfected patients[J].J Viral Hepat,2012,19(11):801-810.

[161]ANTONUCCI G,MAZZOTTA F,ANGELETTI C.Access to treatment for HBV infection and itsconsistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy[J].BMC Res Notes,2013,6:153-160.

[162]ZOUTENDIJK R,ZAAIJER HL,de VRIES-SLUIJS TE.Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV[J].J Infect Dis,2012,206(6):974-980.

[163]ZHANG Y,HU XY,ZHONG S,et al.Entecavir vs lamivudine therapy for naive patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure[J].World J Gastroenterol,2014,20(16):4745-4752.

[164]GARG H,SARIN SK,KUMAR M,et al.Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure[J].Hepatology,2011,53(3):774-780.

[165]YU S,JIANQIN H,WEI W,et al.The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure:a meta-analysis[J].Ann Hepatol,2013,12(3):364-372.

[166]ZHANG X,AN Y,JIANG X,et al.Entecavir versus Lamivudine therapy for patients with chronic hepatitis B-associated liver failure:a meta-analysis[J].Hepat Mon,2014,14:e19164.

[167]XIE F,YAN L,LU J,et al.Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure:meta-analysis[J].PLoS One,2013,8(1):e54773.

[168]SUN P,DONG X,CHENG X,et al.Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment:a systematic review and meta-analysis[J].PLoS One,2014,9(7):e102761.

[169]YIN J,LI N,HAN Y,et al.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma:a two-stage longitudinal clinical study[J].J Clin Oncol,2013,31(29):3647-3655.

[170]CHOLONGITAS E,PAPATHEODORIDIS GV.High genetic barrier nucleos(t)ide analogue(s)for prophylaxis from hepatitis B virus recurrence after liver transplantation:a systematic review[J].Am J Transplant,2013,13(2):353-362.

[171]YI NJ,CHOI JY,SUH KS,et al.Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin[J].J Gastroenterol,2013,48(12):1401-1410.

[172]TEPERMAN LW,POORDAD F,BZOWEJ N,et al.Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation[J].Liver Transpl,2013,19(6):594-601.

[173]LAI CL,YUEN MF.Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy[J].Hepatology,2013,57(1):399-408.

[174]BZOWEJ NH.Optimal management of the hepatitis B patient who desires pregnancy or is pregnant[J].Curr Hepat Rep,2012,11(2):82-89.

[175]PAN CQ,DUAN ZP,BHAMIDIMARRI KR,et al.An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus[J].Clin Gastroenterol Hepatol,2012,10(5):452-459.

[176]ZHANG H,PAN CQ,PANG Q,et al.Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice[J].Hepatology,2014,60(2):468-476.

[177]GREENUP AJ,TAN PK,NGUYEN V,et al.Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus[J].J Hepatol,2014,61(3):502-507.

[178]SARKAR M,TERRAULT NA.Ending vertical transmission of hepatitis B:the third trimester intervention[J].Hepatology,2014,60(2):448-451.

[179]DELLA CORTE C,NOBILI V,COMPARCOLA D.Management of chronic hepatitis B in children:an unresolved issue[J].J Gastroenterol Hepatol,2014,29(5):912-919.

[180]SAADAH OI,SINDI HH,BIN-TALIB Y,et al.Entecavir treatment of children 2-16 years of age with chronic hepatitis B infection[J].Arab J Gastroenterol,2012,13(2):41-44.

[181]JONAS MM,CHANG MH,SOKAL E,et al.Randomized,controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B[J].Hepatology,2015.[Epub ahead of print]